Systematic review and meta-analysis compares subcutaneous versus intravenous PD-1/PD-L1 inhibitors for solid tumors
Subcutaneous shots match intravenous drugs for cancer survival and response rates in solid tumors
This systematic review and meta-analysis of 1243 patients with solid tumors found no significant difference in overall survival, progression…
A large review found that giving cancer drugs under the skin works just as well as the traditional vein injection for patients with solid tu…
Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 show improved risk discrimination for immune-toxicity-associated systemic injury
New Tool Predicts Immune Drug Organ Damage
This translational multicohort study evaluated patients receiving immune checkpoint inhibitors in United States electronic health record dat…
A new system helps doctors predict which patients might suffer dangerous organ injury from powerful cancer drugs, giving them time to act so…
Narrative review discusses immune checkpoint inhibitors in lung cancer patients
New Hope for Lung Cancer Patients
This narrative review examines immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 and CTLA-4 inhibitors, for patients with lung cance…
Lung cancer patients now have a fighting chance as new medicines help the body's own immune system attack tumors instead of just killing cel…